Behind the science

Three crucial facts everyone should know about RSV

Our head of vaccines R&D Phil Dormitzer shares what scientists have learned about the lesser known respiratory virus to empower patients to take action and protect themselves against it.

Our strategy

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.

Our R&D focus is on four therapeutic areas: infectious diseases, HIV, respiratory/immunology and oncology

Infectious diseases
1 in 3
of us will be affected by shingles in our lifetime
HIV
38m
people in 2021 are living with HIV worldwide
Respiratory/Immunology
25yrs
of leading research to help people with inflammatory conditions
Oncology
~10m
people died from cancer in 2020, making it a leading cause of death worldwide

Life at GSK

How we help people thrive 

Studio portrait - light background - 8

Culture

Man smiling

Growth

Man smiling

Diversity, equity and inclusion

Scientists conversing over skeletal formulae

Wellbeing

icon

Positively impacting society and the planet

Baby laughing

Access

We are making our products affordable and available to more people around the world through responsible pricing, strategic access programmes and partnerships.

Scientist inspecting a vial

Global health and health security

We are committed to using our science, our partnerships, and the knowledge we’ve gained from addressing the world’s biggest health challenges to improve health globally.

Young girl leaving front door

Environment

We're committed to work towards a net zero, nature positive, healthier planet, with ambitious goals set for 2030 and 2045.

Scientist in laboratory

Diversity, equity and inclusion

Our work supports the health of all kinds of people. To meet our diverse patients' needs better, we need diversity in our clinical trials and to support our own people to thrive as part of an inclusive team.

Group of scientists in the lab

Ethical standards

Our culture guides our people to do the right thing and act on any concerns they have.

Scientist in conversation

Product governance

Ensuring the quality, safety and reliable supply of our products is critical to our purpose of uniting science, talent and technology to get ahead of disease together.

INVESTORS

We announced our full year and fourth quarter 2023 results on Wednesday 31 January

View latest results